Amanda Ramos, MD, a first-year fellow at the Massachusetts General Hospital in Boston, discusses the future potential of checkpoint inhibition therapy in the treatment of patients with recurrent endometrial cancers.
Amanda Ramos, MD
Advertisement
Articles by Amanda Ramos, MD
Advertisement
Latest Updated Articles
Exploring Checkpoint Inhibition in Endometrial CancersPublished: May 15th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
